The Histidine-Rich Calcium Binding Protein in Regulation of Cardiac Rhythmicity by Arvanitis, Demetrios A. et al.
Open Research Online
The Open University’s repository of research publications
and other research outputs
The Histidine-Rich Calcium Binding Protein in
Regulation of Cardiac Rhythmicity
Journal Item
How to cite:
Arvanitis, Demetrios A.; Vafiadaki, Elizabeth; Johnson, Daniel M.; Kranias, Evangelia G. and Sanoudou, Despina
(2018). The Histidine-Rich Calcium Binding Protein in Regulation of Cardiac Rhythmicity. Frontiers in Physiology, 9,
article no. 1379.
For guidance on citations see FAQs.
c© 2018 The Authors
Version: Version of Record
Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.3389/fphys.2018.01379
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
fphys-09-01379 September 25, 2018 Time: 18:2 # 1
REVIEW
published: 27 September 2018
doi: 10.3389/fphys.2018.01379
Edited by:
Gaetano Santulli,
Columbia University, United States
Reviewed by:
Crystal M. Ripplinger,
University of California, Davis,
United States
Yoram Etzion,
Ben-Gurion University of the Negev,
Israel
Pietro Mesirca,
Centre National de la Recherche
Scientifique (CNRS), France
*Correspondence:
Despina Sanoudou
dsanoudou@med.uoa.gr;
dsanoudou@bioacademy.gr
Specialty section:
This article was submitted to
Cardiac Electrophysiology,
a section of the journal
Frontiers in Physiology
Received: 21 July 2018
Accepted: 11 September 2018
Published: 27 September 2018
Citation:
Arvanitis DA, Vafiadaki E,
Johnson DM, Kranias EG and
Sanoudou D (2018) The
Histidine-Rich Calcium Binding
Protein in Regulation of Cardiac
Rhythmicity. Front. Physiol. 9:1379.
doi: 10.3389/fphys.2018.01379
The Histidine-Rich Calcium Binding
Protein in Regulation of Cardiac
Rhythmicity
Demetrios A. Arvanitis1, Elizabeth Vafiadaki1, Daniel M. Johnson2,
Evangelia G. Kranias1,3 and Despina Sanoudou1,4*
1 Molecular Biology Division, Biomedical Research Foundation, Academy of Athens, Athens, Greece, 2 Department
of Cardiothoracic Surgery, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, Netherlands,
3 Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH,
United States, 4 Clinical Genomics and Pharmacogenomics Unit, 4th Department of Internal Medicine, Attikon Hospital,
Medical School, National and Kapodistrian University of Athens, Athens, Greece
Sudden unexpected cardiac death (SCD) accounts for up to half of all-cause mortality
of heart failure patients. Standardized cardiology tools such as electrocardiography,
cardiac imaging, electrophysiological and serum biomarkers cannot accurately predict
which patients are at risk of life-threatening arrhythmic episodes. Recently, a common
variant of the histidine-rich calcium binding protein (HRC), the Ser96Ala, was identified
as a potent biomarker of malignant arrhythmia triggering in these patients. HRC has
been shown to be involved in the regulation of cardiac sarcoplasmic reticulum (SR) Ca2+
cycling, by binding and storing Ca2+ in the SR, as well as interacting with the SR Ca2+
uptake and release complexes. The underlying mechanisms, elucidated by studies at
the molecular, biochemical, cellular and intact animal levels, indicate that transversion of
Ser96 to Ala results in abolishment of an HRC phosphorylation site by Fam20C kinase
and dysregulation of SR Ca2+ cycling. This is mediated through aberrant SR Ca2+
release by the ryanodine receptor (RyR2) quaternary complex, due to the impaired
HRC/triadin interaction, and depressed SR Ca2+ uptake by the sarco/endoplasmic
reticulum Ca2+ ATPase (SERCA2) pump, due to the impaired HRC/SERCA2 interaction.
Pharmacological intervention with KN-93, an inhibitor of Ca2+/calmodulin-dependent
protein kinase II (CaMKII), in the HRC Ser96Ala mouse model, reduced the occurrence
of malignant cardiac arrhythmias. Herein, we summarize the current evidence on the
pivotal role of HRC in the regulation of cardiac rhythmicity and the importance of HRC
Ser96Ala as a genetic modifier for arrhythmias in the setting of heart failure.
Keywords: calcium, homeostasis, contractility, ion channels, arrhythmia
INTRODUCTION
Arrhythmias are potentially life-threatening electrical manifestations of the heart, which are
difficult to predict and treat. The underlying molecular and cellular mechanisms leading to
arrhythmia triggering are only partly known. Previously, Na+ and K+ ion channels, which are
known to modulate depolarization and repolarization, had been a focus of studies on arrhythmia
pathogenesis (Remme and Bezzina, 2010; Schmitt et al., 2014). However, many cases cannot be
explained by impairments in these two types of channels, suggesting that additional genes, such
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as calcium (Ca2+) homeostasis regulators, are implicated in
cardiac arrhythmias (London, 2013). Indeed, abnormal Ca2+
handling by the sarcoplasmic reticulum (SR) has emerged as
a significant contributor to arrhythmogenesis. This is based
on accumulating evidence on the crucial role of SR Ca2+
homeostasis in cardiac contraction, the direct association
of human mutations in SR Ca2+ release components with
arrhythmias, as well as alterations in the expression levels
and activity of key Ca2+ handling proteins in human heart
failure (Antoons and Sipido, 2008; Pritchard and Kranias,
2009; Lompre et al., 2010; Landstrom et al., 2017). One of
these proteins, namely histidine-rich calcium binding protein
(HRC) has attracted considerable attention over the past decade,
since the identification of the HRC Ser96Ala gene variant was
associated with increased risk for malignant arrhythmias and
sudden cardiac death (SCD) in dilated cardiomyopathy patients
(Arvanitis et al., 2008, 2011; Pritchard and Kranias, 2009).
Deciphering the fine mechanisms of HRC contribution to cardiac
physiology and pathophysiology could hold answers for the
treatment of arrhythmias.
Herein, we summarize the major evidence on the crucial
role of HRC in the regulation of cardiac rhythmicity through
modulation of SR Ca2+ homeostasis, the clinical and molecular
defects associated with the HRC genetic variant Ser96Ala, as
well as potential therapeutic approaches targeting the underlying
molecular defects in Ser96Ala carriers to prevent arrhythmia
triggering.
THE HISTIDINE-RICH CALCIUM
BINDING PROTEIN
Histidine-rich calcium binding protein is a 170 kDa protein
that is primarily expressed in striated muscles and arteriolar
smooth muscle cells (Hofmann et al., 1989a,b; Pathak et al., 1992;
Anderson et al., 2004). It is a highly charged molecule, with
over 30% of the protein composed of acidic residues and 13% of
histidine (Hofmann et al., 1989b). Based on its deduced amino
acid sequence, HRC contains the following structural features:
(1) an amino-terminal 27-residue signal sequence that is believed
to target the protein to the SR; (2) a highly repetitive region
containing 9 nearly identical tandem repeats of 29 residues,
each consisting of a histidine-rich sequence HRHRGH and a
stretch of 10–11 acidic amino acids that is believed to have
Ca2+ binding properties; (3) a 13-residue stretch of polyglutamic
acid; and (4) a cluster of 14 closely spaced cysteine residues,
with the repeating pattern of Cys-X-X-Cys suggestive of a heavy
metal binding domain, at the carboxyl terminus (Hofmann et al.,
1989b). Detailed biochemical analysis has established that HRC
is a low-affinity, high capacity Ca2+ binding protein. Although
there is no Ca2+ binding motif in HRC, it is presumed that the
acidic repeats constitute its Ca2+ binding sites (Hofmann et al.,
1989b). It is noteworthy that HRC contains more acidic clusters
than the other major SR Ca2+ binding protein, calsequestrin
(CSQ), indicating the high capacity of HRC for Ca2+ binding
(Hofmann et al., 1989a; Picello et al., 1992). These structural
features render HRC an important regulator of cardiomyocyte
SR Ca2+ homeostasis, as revealed by in depth investigations at
the in vitro, ex vivo, and in vivo levels.
THE ROLE OF HRC AS A PROGNOSTIC
MARKER OF ARRHYTHMIAS
Heart failure is characterized by impaired cytosolic Ca2+
handling, a process predominantly governed by the SR, which
leads to diastolic and systolic dysfunction of the cardiomyocyte
and ultimately of the heart pump (Morgan et al., 1990). Early
reports on the association of HRC with cardiac pathophysiology
proposed a role in dystrophic cardiac calcification of inbred
mouse strains (van den Broek et al., 1998). HRC has been
previously associated with two human autosomal dominant
cardiac diseases, the isolated cardiac conduction (de Meeus et al.,
1995) and the familial heart block type 1 (Brink et al., 1995).
Further studies in end-stage human heart failure reported a
significant decrease in HRC protein levels (Fan et al., 2004), a
finding also observed in experimental heart failure in mice (Fan
et al., 2004) and dogs (Gupta et al., 2009). Collectively, these
observations implicated HRC in cardiac pathophysiology and
raised the need for further investigations on its precise role and
value in the clinical setting.
In 2008 our group was the first to show a direct association
of the HRC Ser96Ala polymorphism with malignant ventricular
arrhythmias. Through the study of 123 idiopathic dilated
cardiomyopathy (DCM) patients (referred to hospital for
diagnosis or treatment of heart failure, including implantable
cardioverter-defibrillator (ICD) implantation) and 96 healthy
controls, the HRC genetic variant Ser96Ala was found to
have a statistically significant association with malignant
ventricular arrhythmias and SCD in the patients (Arvanitis
et al., 2008). Specifically, idiopathic DCM patients harboring
the Ala/Ala variant had a fourfold increased risk of SCD
compared to homozygotes for the Ser allele. The HRC Ser96Ala
polymorphism was an independent predictor of life-threatening
ventricular arrhythmias controlled by age, sex, left ventricular
ejection fraction, atrial fibrillation, left bundle branch block
or medication. Interestingly, further genetic analysis showed
that approximately 60% of the general population has at
least one copy of Ser96Ala, however, only those individuals
suffering from DCM and carrying this polymorphism appear
to be susceptible to arrhythmogenesis. Consequently, the HRC
Ser96Ala polymorphism has a significant prognostic value.
UNDERSTANDING THE ROLE OF HRC IN
ARRHYTHMIAS THROUGH IN VITRO
AND IN VIVO RODENT MODELS
One of the first studies to explore the role of HRC in SR Ca2+
handling, employed rat cardiomyocytes overexpressing HRC,
and demonstrated that increased HRC levels lead to a 30%
increase in SR Ca2+, accompanied by a 40% decrease in SR
Ca2+ release, ultimately resulting in depressed cardiomyocyte
shortening and re-lengthening. The depressed contraction
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of the HRC-infected cardiomyocytes remained even after
maximal isoproterenol stimulation. At the molecular level, HRC
overexpresssion was accompanied by increase of the ryanodine
receptor (RyR2) quaternary complex components junctin and
triadin (Fan et al., 2004).
This study was followed by the generation of a transgenic
mouse model overexpressing HRC (by 3-fold). Genetically
modified mouse models, as well as their explanted hearts and
isolated cardiomyocytes, have long been used to delineate the
effects of various genes and mutations thereof on cardiac
arrhythmogenesis. Although these models have a number of
limitations, they remain one of the major tools available for in
depth cellular and physiological studies at the in vivo, ex vivo, and
in vitro levels (Davis et al., 2012; Huang, 2017).
In this setting, the increased cardiac HRC levels were
associated with impaired SR Ca2+ uptake (by 35%) and
attenuated cardiomyocyte Ca2+ transient decay (by nearly 40%).
Possibly as a compensatory mechanism, there was a marked
increase of the Na+−Ca2+ exchanger (NCX) and triadin protein
levels in myocytes isolated from these mice. At the cellular
level, however, neither NCX mediated Ca2+ extrusion nor RyR2
SR Ca2+ release was elevated. In fact, the depressed SR Ca2+
sequestration was associated with an attenuated rate of Ca2+
extrusion. Interestingly, as the mice aged, they presented with
impaired cardiomyocyte Ca2+ cycling, leading to abnormal
cardiac remodeling and congestive heart failure (Gregory et al.,
2006).
Similarly, the implications of the lack of HRC were
investigated at the in vitro and in vivo levels. Initially, HRC
was knocked-down in neonatal rat ventricular cells and HL-
1 cells, using in vitro siRNA technology. This led to increased
activity of RyR2 and SERCA2 whilst SR Ca2+ load was
unaffected. The in vivo adeno-associated virus (AAV)-mediated
HRC knock-down in mice with or without transverse aortic
constriction (TAC)-induced heart failure, led to decreased
fractional shortening and increased cardiac fibrosis compared
with control. At the molecular level these findings were associated
with increased phosphorylation of RyR2, CaMKII, p38 MAPK,
and phospholamban (PLN). Thus, down-regulation of HRC led
to significant deterioration of cardiac function following TAC-
induced heart failure (Park et al., 2012).
Following these studies, HRC-knockout (KO) mice were
generated. Although morphologically and histologically they
were normal, compared to wild-type, at the cellular level,
the HRC-KO mouse cardiomyocytes exhibited significantly
enhanced contractility, Ca2+ transients, and maximal SR Ca2+
uptake rates. They also presented with an increased number of
spontaneous SR Ca2+ releases and delayed afterdepolarizations,
perhaps driven by the increased number of Ca2+ sparks seen
in KO mice compared to controls. Under stress conditions of
1 µmol/L isoproterenol and 5 Hz stimulation, the HRC-KO
isolated cardiomyocytes were found to be five-fold more prone
to after-contractions compared to wild-type mice. After TAC the
HRC-KO mice developed severe cardiac hypertrophy, fibrosis,
pulmonary edema and premature death compared to wild-
types. Isolated cardiomyocytes from TAC treated HRC-KO hearts
exhibited poor contractility and impaired Ca2+-cycling, possibly
due to reduced SERCA2 expression. These data underline the
importance of HRC in the normal physiology of SR Ca2+
handling, as well as in maintaining the integrity of normal cardiac
performance (Park et al., 2013).
Since HRC Ser96Ala has been associated with malignant
ventricular arrhythmias (Arvanitis et al., 2008), the cellular
mechanisms of pathogenesis were investigated initially in
isolated adult rat ventricular cardiomyocytes infected with
adenoviruses encoding the human HRC (hHRC) Ser96 or
Ala96. The hHRC Ala96 exacerbated the inhibitory effects
of hHRC Ser96 on the amplitude of Ca2+ transients, the
prolongation of Ca2+ decay, and the caffeine-induced SR Ca2+
release, indicating a higher SR Ca2+ load. hHRC Ala96 had a
stronger suppressive effect on the maximal SR Ca2+ uptake rate
compared to hHRC Ser96. Furthermore, hHRC Ala96 increased
the frequency of spontaneous Ca2+ sparks, while the hHRC
Ser96 reduced them compared to GFP expressing controls.
Importantly, expression of hHRC Ala96 in cardiomyocytes
from a rat model of post-myocardial infarction heart failure
induced dramatic disturbances of rhythmic Ca2+ transients.
These findings reproduce the arrhythmogenic propensity of
the human HRC Ser96Ala variant carriers when their cardiac
function is compromised in the setting of heart failure (Han et al.,
2011).
A recent study was carried out on a ‘humanized’ mouse
of HRC Ser96Ala, where the murine HRC gene was replaced
by the human homolog, and therefore carried either the wild-
type gene with serine at position 96, or the alanine variant.
The hHRC Ala96 mice displayed poor contractility and Ca2+
cycling compared to hHRC Ser96, in the absence of any
structural or histological abnormalities. The occurrence of
Ca2+ waves was significantly higher but the SR Ca2+ load
was lower in hHRC Ala96 compared to hHRC Ser96. At the
molecular level these findings were attributed to the poor
interaction of HRC Ala96 with triadin, and ultimately with
RyR2 (through triadin). Indeed, the open probability of RyR2
was significantly increased in hHRC Ala96 cardiomyocytes.
Under stress conditions of 1 µmol/L isoproterenol and 5 Hz
stimulation, isolated cardiomyocytes from hHRC Ala96 hearts
presented with 6-fold more aftercontractions and 3-fold more
delayed afterdepolarizations when compared to hHRC Ser96
cardiomyocytes. RyR2 was found to be hyperphoshorylated
by CaMKII at Ser2814. Importantly, treatment of the hHRC
Ala96 derived cardiomyocytes with KN93, a specific inhibitor of
CaMKII, reversed the increase of Ca2+ sparks and waves (Singh
et al., 2013).
Although these studies provided important insights into the
potential arrhythmogenic mechanisms of the Ser96Ala mutation,
they had an inherent issue – a non-murine protein being
produced in the mouse. This could result in interactions of the
human HRC with mouse proteins that may not necessarily take
place when exclusively murine HRC is present. We therefore
pursued an alternative, and perhaps more physiologically relevant
approach, where the mutation was directly introduced in the
mouse gene, at the equivalent site. This led to the development
of the HRC Ser81Ala mouse model, which recapitulated the
human Ser96Ala mutation directly in the mouse HRC protein
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(Tzimas et al., 2017). The HRC Ser81Ala mice presented with
increased mortality over a 12-month period, with 50% of the
Ser81Ala mice dead by 10 months, compared to only 15% of
the wild-type animals. Interestingly, no abnormalities were noted
in the Ser81Ala mouse hearts in terms of cardiac structure
and fibrosis, at least as far as 3–5 months of age, similar
to data from the humanized Ser96Ala mouse. In addition,
cardiac contraction, both in vivo and ex vivo (as measured
by Langendorff preparation), was shown to be significantly
decreased in 3–4-month-old Ser81Ala mice, when compared to
the wild-types, whilst the Ser81Ala mice showed a slight decrease
in intraventricular septum and left ventricular posterior wall
thickness. Further age-related decreases in contractile function
were similar between the two strains. Taken together, these data
indicated that the increased mortality observed in HRC Ser81Ala
mice was unlikely due to acute heart failure, and other factors
should be considered (Tzimas et al., 2017).
Due to the fact that ventricular arrhythmias have been
previously noted in the patient population with the Ser96Ala
variant (Arvanitis et al., 2008), we hypothesized that SCD as a
result of arrhythmias may also be the reason for the increased
mortality in the Ser81Ala mice. We therefore performed a series
of electrophysiological examinations on these mice in vivo.
This work revealed an increased sensitivity of the Ser81Ala
mice to an arrhythmogenic challenge (caffeine/epinephrine
administration) when compared to the wild-type, with more
than 50% of Ser81Ala mice going into ventricular tachycardia,
compared to none of the wild-type animals. We extended these
studies by carrying out experiments in isolated myocytes, where
an increase in aftercontractions, calcium after-transients and
delayed afterdepolarizations were observed in Ser81Ala derived
cells, further supporting the hypothesis that the increase in
mortality is due to arrhythmogenic events (Tzimas et al., 2017).
Interestingly, contraction in myocytes from the Ser81Ala mouse
was not increased, indicating that Ca2+ overload, per se, was not a
driving force for the arrhythmogenic phenotype, as has been seen
in a number of other models and digitalis-induced arrhythmias
(Sipido, 2006; van den Hoogenhof et al., 2018).
Interestingly in heart failure, where arrhythmias may also
ensue, it has been shown that SR Ca2+ load is not increased
(Hasenfuss and Pieske, 2002). In this case arrhythmogenesis may
be due to a variety of other factors, including increased activity of
RyR2 or altered activity of NCX. For these reasons we went on to
investigate if there was an increased spontaneous Ca2+ release in
the Ser81Ala cardiomyocytes. Despite the fact we did not observe
any alterations in Ca2+ spark properties, we did see an increase
in total Ca2+ leak in myocytes isolated from the Ser81Ala
mice, and an increase in Ca2+ wave speed. Furthermore, an
increase in phosphorylation of RyR2 was noted at the CaMKII
phosphorylation site (Ser-2814) under baseline conditions in
Ser81Ala myocytes, whilst no differences were observed at the
protein kinase A (PKA) site of RyR2, or in PLN phosphorylation.
FIGURE 1 | Histidine-rich calcium binding protein complex cellular interactions within the cardiomyocytes. Local SR Ca2+ changes alter the dynamics of HRC
interactions with triadin and SERCA2.
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However, there were no alterations in the levels of the RyR2
protein, whilst an increase was seen in junctin and NCX, and
a decrease in triadin. Additionally, increases in action potential
(AP) duration were noted in the Ser81Ala myocytes, which went
along with an increase in inward (Ca2+) current. Taking all of
these data together, we hypothesized that CaMKII played a key
role in the arrhythmogenic phenotype in the Ser81Ala mouse. At
both the cellular and in vivo levels, inhibition of CaMKII with
KN-93 was indeed able to reduce the number of arrhythmogenic
events.
Despite the fact that further studies should be carried out in
this model, including the potential dyadic structural remodeling
in myocytes, we can summarize that the HRC Ser81Ala mutation
causes arrhythmia via increased spontaneous Ca2+ leak and
longer APs, and this is, at least in part due to CaMKII activity.
This alteration of CaMKII activity could be driven by the
alterations in the local Ca2+ concentration, although the exact
mechanisms of CaMKII activation in this model remains to
be elucidated. Taking all of these data into account, CaMKII
inhibition could be a potential therapeutic target in patients with
similar polymorphisms/mutations.
HRC BINDING PARTNERS AND THEIR
ROLE IN MEDIATING HRC EFFECTS ON
Ca2+ HOMEOSTASIS AND
ARRHYTHMOGENESIS
The SR holds a pivotal role in Ca2+ compartmentalization
within the cardiomyocyte. During each cycle of cardiomyocyte
activation Ca2+ fluxes rapidly back and forth between the cytosol
and the sarcoplasmic reticulum. The SR Ca2+ release occurs
through the opening of the gigantic RyR2 multiprotein complex
under the regulation of triadin and junctin (Gambardella et al.,
2018; Santulli et al., 2018; Slabaugh et al., 2018), while the
energetic transport of cytosolic Ca2+ to the SR is achieved by
SERCA2 under the regulation of PLN (Vafiadaki et al., 2009;
Wang et al., 2011; Kranias and Hajjar, 2012). The HRC protein
interacts with both systems mediating a fine cross talk between
cytosolic Ca2+− spark and decay (Figure 1; Arvanitis et al.,
2007). HRC has been previously shown to be localized to the SR
lumen in cardiac and skeletal muscles (Hofmann et al., 1989a;
Shoshan-Barmatz et al., 1996; Suk et al., 1999) and based on its
structural similarities with CSQ, it was initially suggested to be
functionally associated with SR Ca2+ release (Hofmann et al.,
1989a; Damiani and Margreth, 1991). This was supported by
several studies, clearly demonstrating the direct interaction of
HRC with triadin, an integral SR membrane protein forming
a quaternary complex with the RyR2, CSQ, and junctin (Kim
et al., 1990; Sacchetto et al., 1999, 2001; Lee et al., 2001). HRC
binds to triadin in a Ca2+-dependent manner, with increases in
Ca2+ concentration leading to enhanced interaction between the
two proteins (Sacchetto et al., 2001; Arvanitis et al., 2007; Rani
et al., 2016). Multiple domains of HRC, including the C-terminal
cysteine-rich domain (Sacchetto et al., 1999, 2001; Arvanitis et al.,
2007) and the histidine-rich and acidic repeats (Lee et al., 2001),
have been shown to interact with triadin. Interestingly, HRC
interacts with triadin’s luminal KEKE motif, a region which is
also implicated in CSQ and RyR2 binding (Lee et al., 2001; Rani
et al., 2016). Given this overlap on triadin’s minimal binding
region, a biochemical study recently examined the potential
competition between CSQ, HRC and RyR2 for triadin binding.
Using increasing concentrations of RyR2 or CSQ peptides in
immunoprecipitation assays, HRC was demonstrated to compete
with RyR2 and CSQ for binding to triadin (Rani et al., 2016).
These findings, indicate the regulatory nature of these protein
associations that are tightly controlled by Ca2+ concentration
toward effective regulation of RyR2 function and SR Ca2+ release.
The possibility that HRC can bind to RyR2 independently of
triadin, was suggested by a study utilizing the HEK293 cell culture
system which lacks endogenous triadin protein (Zhang et al.,
2014). However, as these findings were obtained solely from
microscopy-based assays, and no further evidence has emerged
since then to support this notion, additional work is required
to establish this association. Overall, based on its association
with triadin, HRC is believed to modulate RyR2 function and SR
Ca2+ release by conferring refractoriness to SR Ca2+ release and
exerting a presumably beneficial effect on SR Ca2+ reloading at
intermediate Ca2+ concentrations (Rani et al., 2016).
In addition to triadin, we have demonstrated that HRC
directly interacts with SERCA2a, the key enzyme mediating SR
Ca2+ uptake (Arvanitis et al., 2007). Similarly to the HRC-triadin,
the HRC-SERCA2 interaction is also Ca2+-dependent, but with
maximal binding occurring at low Ca2+ concentration, and
a diminishing HRC-SERCA2 association with increasing Ca2+
concentrations (Arvanitis et al., 2007). The protein domains
involved in this interaction include the amino-terminal fragment
of SERCA2 that projects into the SR lumen (amino acid
residues 74–90) and the second histidine- and glutamic acid-rich
domain of HRC (amino acids 320–460) (Arvanitis et al., 2007).
FIGURE 2 | Histidine-rich calcium binding protein functional significance in
cardiac physiology and pathophysiology.
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Interestingly, the HRC domain binding to triadin is distinct,
and involves its cysteine-rich domain (amino acids 609–699) at
the carboxyl terminal fragment (Sacchetto et al., 2001; Arvanitis
et al., 2007). The choice of HRC binding partner, which is tightly
controlled by Ca2+ concentrations, determines the HRC effect
on SR Ca2+ cycling. At low SR Ca2+ load HRC interacts with
SERCA2 and inhibits its activity. However, upon increases in
SR Ca2+ concentration, HRC dissociates from SERCA2, exhibits
enhanced binding to triadin, and modulates SR Ca2+ release
(Arvanitis et al., 2011). Through this dual association with
SERCA2 and triadin, HRC is implicated in both SR Ca2+ uptake
and Ca2+ release, with defects in both processes observed upon
HRC overexpression or ablation (Gregory et al., 2006; Park
et al., 2013). HRC may therefore represent a key mediator of
the fine cross-talk between these two processes in cardiomyocyte
contraction and relaxation. Any factors modulating HRC, such
as post-translational modifications (see section below) or gene
sequence variations (e.g., the genetic variant Ser96Ala), could
affect these protein associations with direct implications in SR
Ca2+ cycling and arrhythmogenesis.
Indeed, acute overexpression of the HRC Ser96Ala human
variant in cell culture systems significantly increased the
binding of HRC Ser96Ala to SERCA2, an effect that was
associated with enhanced inhibition of SERCA2 activity and
thus reduced maximal SR Ca2+ uptake rate (Han et al.,
2011). Importantly, HRC Ser96Ala increased the frequency of
spontaneous Ca2+ sparks, suggesting enhanced RyR2 activity,
and leading to increased uncontrolled SR Ca2+ release (Han
et al., 2011). Similarly, as mentioned above, cardiomyocytes from
the humanized HRC Ser96Ala mouse model exhibited increased
RyR2 activity, enhanced propensity for spontaneous SR Ca2+
release and arrhythmias (Singh et al., 2013). Collectively, these
studies have clearly demonstrated the functional significance of
HRC interactions with SERCA2 and triadin toward effective
regulation of SR Ca2+ uptake and release (Figure 2). Defects
in HRC function due to genetic mutations lead to aberrant
SR Ca2+ cycling and enhanced propensity toward arrhythmia
triggering.
HRC POST-TRANSLATIONAL
MODIFICATION
Initial reports on the HRC gene and protein functions described
the phosphorylation of HRC by multiple kinases, including PKA
and CaMKII (Damiani and Margreth, 1991; Damiani et al., 1995),
as well as casein kinase II (CKII), an endogenous kinase which
associates with SR membranes (Orr and Shoshan-Barmatz, 1996;
Shoshan-Barmatz et al., 1996). Although PKA and CaMKII can
phosphorylate HRC in vitro, these phosphorylations may not
occur in vivo since HRC is a luminal protein and is not accessible
to these cytoplasmic kinases (Hofmann et al., 1989a; Suk et al.,
1999). It has been postulated that phosphorylation of HRC by
CKII decreased the affinity of RyR2 for Ca2+, although it was
FIGURE 3 | Histidine-rich calcium binding protein phosphorylation by Fam20C at Ser96 affects the affinity of HRC interactions with SERCA2 and triadin while the
Ala96 variant remains unaffected.
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not clear whether this phosphorylation mediates a direct effect
on RyR2 activity (Orr and Shoshan-Barmatz, 1996; Shoshan-
Barmatz et al., 1996).
The discovery of the HRC Ser96Ala variant association with
life-threatening ventricular arrhythmias in the setting of dilated
cardiomyopathy, led to the hypothesis of abolishment of a
potential phosphorylation site on HRC, with direct implication
in downstream molecular and cellular processes. Indeed,
bioinformatical analysis showed that HRC Ser96, an evolutionary
conservative amino-acid position, could be phosphorylated
(Arvanitis et al., 2008). In vivo phosphoproteomic studies of
healthy human skeletal muscle found that HRC is phosphorylated
at six serine amino acid residues, namely Ser119, Ser431,
Ser563, Ser567, Ser157/Ser159, and Ser170/Ser171 (Hojlund
et al., 2009). The authors predicted, using bioinformatical
analysis, that the majority of these sites, (Ser119, Ser170
or Ser171, Ser431, and Ser567), could be phosphorylated by
the luminally located CKII, while Ser157 or Ser159 may
be phosphorylated by protein kinase B (PKB), and Ser563
by the mitogen-activated protein kinase 8 (MAPK8) or the
glycogen synthase kinase 3 beta (GSK3B). Another study, which
focused on in vitro dephosphorylation of cardiac proteins,
demonstrated that HRC is phosphorylated at five positions
(Ser104, Ser129, Ser249, Ser324, and Ser466) in wild-type hearts
and can be dephosphorylated in vitro by alkaline phosphatase
(Husberg et al., 2012). Although these studies were valuable
for achieving a deeper understanding on post-translational
modifications of wild-type HRC in healthy human skeletal
and cardiac muscles, the status of HRC Ser96 remained
unaddressed.
Recently, a new kinase, family with sequence similarity 20C
(Fam20C) that phosphorylates S-x-E/pS motifs on proteins was
found to be responsible for the majority of the extracellular
phosphoproteome (Tagliabracci et al., 2015). Located within
the ER and the Golgi apparatus, Fam20C phosphorylates a
multitude of proteins including HRC Ser96, Ser119, Ser145,
Ser358, Ser409, Ser431, Ser494, and Ser567. These findings
not only identify Fam20C as the predominant kinase involved
in the protein secretory pathway of cells but also suggest
that Fam20C is a potential pharmacological target, affecting a
multiple of cellular processes ranging from cell adhesion and
migration to treatment against HRC driven life-threatening
ventricular arrhythmias. Further proteomic and biochemical
investigations under native or post-phosphatase treated whole-
cardiac homogenates, clearly demonstrated that Fam20C is
the kinase for HRC in vivo (Tagliabracci et al., 2015). These
findings were supported by cell culture studies of co-expression
of HRC and Fam20C in rat cardiomyoblasts, and expression
of HRC in human osteosarcoma cells with CRISPR/Cas9
knockout of Fam20C. The importance of HRC phosphorylation
at position 96 was demonstrated when HRC KO mouse
heart derived primary cardiomyocytes, which exhibit increased
arrhythmogenicity, were infected with pseudo-phosphorylated
(HRC-Asp96) encoding adenoviruses, which alleviated the
arrhythmias. In addition, the Fam20C-phosphorylated HRC
showed a stronger interaction with triadin and a weaker
interaction with SERCA2 by co-immunoprecipitation studies,
while the unphosphorylated HRC showed a stronger interaction
with SERCA2 (Figure 3). Collectively, these data suggest that
Fam20C is, at least in part, responsible for HRC phosphorylation,
and that the variant Ser96Ala changes the affinity of HRC
interactions with triadin and SERCA2 (Pollak et al., 2017).
Further experiments with specific inhibitors of Fam20 will
be required to clarify the role of Fam20-phosphorylation in
arrhythmia generation.
CONCLUSION
Studies on HRC function over the past decade, using in vitro
and in vivo approaches at the molecular, cellular, tissue, organ,
and whole organism levels have demonstrated its importance in
cardiomyocyte physiology and pathophysiology. HRC mediates a
cross-talk between SR Ca2+ uptake and release, regulating both
systems and acting as a Ca2+ sensor. Importantly, the function
of HRC is regulated by its phosphorylation at Ser96 and human
carriers with the Ser96Ala variant are predisposed to cardiac
arrhythmias under stress conditions. Thus this variant may serve
as a biomarker for the identification of cardiovascular disease
patients at risk for SCD.
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